A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

ClinicalTrials.gov ID: NCT04225923

Public ClinicalTrials.gov record NCT04225923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.

Study identification

NCT ID: NCT04225923
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Nobelpharma; Industry
Enrollment: 87 participants

Conditions and interventions

Conditions

Cytomegalovirus Disease

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 76 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 1, 2020 (Actual)
Primary completion: Nov 2, 2022 (Actual)
Completion: Feb 8, 2023 (Actual)
Last update posted: Jun 17, 2025

2020 – 2023

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Mayo Clinic - Scottsdale	Phoenix	Arizona	85054	—
California Institute of Renal Research	La Mesa	California	91942	—
Piedmont Healthcare	Atlanta	Georgia	30309	—
Augusta University Medical Center	Augusta	Georgia	30912	—
University of Michigan	Ann Arbor	Michigan	48084	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Washington University School of Medicine	St Louis	Missouri	63110	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
The Christ Hospital	Cincinnati	Ohio	45219	—
University of Cincinnati College of Medicine	Cincinnati	Ohio	45219	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Renal Disease Research Institute	Dallas	Texas	75235	—
University of Texas Southwestern	Dallas	Texas	75390	—
University of Wisconsin - Madison	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04225923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 17, 2025 · Synced Nov 10, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04225923 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →